A Phase 1 Trial of Belzupacap Sarotalocan (AU-011)
Phase 1
55
about 4.5 years
18+
11 sites in AR, CA, NY +3
Why this study is shown
What this study is about
This trial is testing the safety and feasibility of a new treatment called AU-011 for bladder cancer. The treatment involves injections with or without laser application, administered to adults.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take AU-011
- 2.Take AU-011 in Combination with Medical Laser Administration
- 3.Take AU-011 in Combination with Medical Laser Adminstration
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Safety of AU-011: Incidences of SAEs and DLTs
Secondary: Complete response (CR) rate, Durable CR rate, Duration of response (DoR), Recurrence-free survival (RFS)
therapeutic
Oncology